#Foralumab

SciTech Chronicles. . . . . . . . .Mar 1st, 2025 Deeds will not be less valiant because they are unpraised. Vol II No 54 318 links Curated Children of primary school age demonstrate the h...

SciTech Chronicles. . . . . . . . .Mar 1st, 2025

bit.ly/stc030125

#associative #learning #infants #adolescents #cognitive #emotional #serotonin #social #TBI #ant-CD3 #CNS #Foralumab ##Bété #Hunteria #Oil-Palms #rainforests #Cached-DFL #model #privacy #delay-tolerant

Breakthrough MS Treatment Shows Promise: 100% Patient Response Rate in Expanded Trial Tiziana's intranasal foralumab delivers positive outcomes in multiple sclerosis program, with all initial patients showing improvement or stability within 6 months.

#foralumab
#MultipleSclerosis
#Non active SPMS

Interesting news :

"Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program"

ClinicalTrials.gov

#MS
#MultipleSclerosis

Novartis has new trial for nonactive SPMS recruiting soon

Key inclusions

PPMS and SPMS
Ages 18-60 inclusive
Disease less than 15 years
Lumbar punctures required

Unfortunately I do not qualify for this one.

Waiting on #foralumab trial

clinicaltrials.gov/study/NCT066...

Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease - Tiziana Life Sciences NEW YORK, September 19, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead develop...

Nasally administered #Foralumab is a promising therapeutic for numerous neuroinflammatory and neurodegenerative diseases. Secondary Progressive, Multiple Sclerosis #SPMS #Alzheimers
Amyotrophic Lateral Sclerosis #ALS www.tizianalifesciences.com/tiziana-life...